The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SIGA | +40.34% | +68.2% | +10.95% | +119% |
| S&P | +16.23% | +94.45% | +14.22% | +622% |
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The firm develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand. The company was founded by Steven Oliveira on December 28, 1995 and is headquartered in New York, NY.
The company has only one product: a monkeypox vaccine.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $81.12M | 271.9% |
| Gross Profit | $55.57M | 484.9% |
| Gross Margin | 68.50% | 24.9% |
| Market Cap | $465.80M | -4.7% |
| Market Cap / Employee | $10.13M | 0.0% |
| Employees | 46 | 2.2% |
| Net Income | $35.48M | 1836.2% |
| EBITDA | $45.82M | 3653.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $182.46M | 70.6% |
| Accounts Receivable | $6.49M | -27.6% |
| Inventory | 35.6 | -36.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.50M | -54.5% |
| Short Term Debt | $0.57M | 8.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 38.40% | -11.1% |
| Return On Invested Capital | 32.73% | 6.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $63.08M | 960.0% |
| Operating Free Cash Flow | $63.08M | 959.6% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 5.61 | 7.25 | 8.07 | 5.68 | -11.73% |
| Price to Book | 2.57 | 2.29 | 1.64 | 2.16 | -27.26% |
| Price to Sales | 2.79 | 3.09 | 3.25 | 2.60 | -17.30% |
| Price to Tangible Book Value | 2.59 | 2.30 | 1.65 | 2.16 | -27.35% |
| Price to Free Cash Flow TTM | 16.82 | 70.88 | 20.38 | 6.14 | -64.93% |
| Enterprise Value to EBITDA | 576.74 | 4.81 | -108.68 | 6.25 | -98.26% |
| Free Cash Flow Yield | 5.9% | 1.4% | 4.9% | 16.3% | 185.13% |
| Return on Equity | 58.4% | 28.7% | 25.5% | 43.6% | -24.27% |
| Total Debt | $1.54M | $1.35M | $1.26M | $1.07M | -34.08% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
